Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    NCT01090414
Previous Study | Return to List | Next Study

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01090414
First received: March 17, 2010
Last updated: October 23, 2014
Last verified: October 2014
  Purpose

This is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with hematologic malignancies who complete other idelalisib studies. It provides the opportunity for patients to continue treatment as long as the patient is deriving clinical benefit. Patients will be followed according to the standard of care as appropriate for their type of cancer. The dose of idelalisib will generally be the same as the dose that was administered at the end of the prior study, but may be titrated up to improve clinical response or down for toxicity. Patients will be withdrawn from the study if they develop progressive disease, unacceptable toxicity related to idelalisib, or if they no longer derive clinical benefit in the opinion of the investigator.


Condition Intervention Phase
Chronic Lymphocytic Leukemia
Lymphoma, Non-Hodgkin
Drug: Idelalisib
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies

Resource links provided by NLM:


Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Overall response rate [ Time Frame: Up to 7 years ] [ Designated as safety issue: No ]
    Overall response rate (ORR) is defined as the proportion of participants who achieve complete response (CR), partial response (PR), or minor response (MR; for Waldenström's macroglobulinemia [WM] only).

  • Safety as assessed by incidence of grade ≥ 3 adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 [ Time Frame: Up to 7 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Duration of Response [ Time Frame: Up to 7 years ] [ Designated as safety issue: No ]
    Duration of response (DOR) is defined as the interval from the first documentation of CR, PR, or MR (for WM) to the earlier of the first documentation of definitive disease progression or death from any cause.

  • Progression-free survival [ Time Frame: Up to 7 years ] [ Designated as safety issue: No ]
    Progression-free survival (PFS) is defined as the interval from enrollment in the parent study to the earlier of the first documentation of definitive disease progression (excluding lymphocytosis alone) or death from any cause.

  • Overall survival [ Time Frame: Up to 7 years ] [ Designated as safety issue: No ]
    Overall survival (OS) is defined as the interval from the start of study treatment in the parent study to death from any cause.

  • Time to response [ Time Frame: Up to 7 years ] [ Designated as safety issue: No ]
    Time to response (TTR) is defined as the interval from first dose to the first documentation of CR or PR.


Estimated Enrollment: 100
Study Start Date: March 2010
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Idelalisib
Participants will receive up to 300 mg of idelalisib once or twice daily until disease progression or unacceptable toxicity.
Drug: Idelalisib
Idelalisib tablets administered orally
Other Names:
  • Zydelig®
  • GS-1101
  • CAL-101

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with hematologic malignancies completing a prior idelalisib study with a clinical benefit are eligible
  • Women of childbearing potential must have a negative pregnancy test to be eligible
  • Male patients, and female patients of childbearing potential, must agree to use method(s) of contraception specified in the protocol

Exclusion Criteria:

  • Patients who are unwilling or unable to comply with the protocol are not eligible
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01090414

Locations
United States, Alabama
Clearview Cancer Institute
Huntsville, Alabama, United States, 35805
United States, California
UCLA
Los Angeles, California, United States, 90095-1678
Stanford Cancer Center
Palo Alto, California, United States, 94304-5548
United States, Maryland
Center for Cancer & Blood Disorders, PC
Bethesda, Maryland, United States, 20817
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
Long Island Jewish medical Center
New Hyde Park, New York, United States, 11042
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Mount Sinai School of Medicine
New York, New York, United States, 10029
Weill Medical College of Cornell
New York, New York, United States, 10021
United States, Ohio
The Ohio State University Medical Center
Columbus, Ohio, United States, 43210
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon, United States, 97477
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
United States, Texas
MD Anderson Cancer and Research Center
Houston, Texas, United States, 77030
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Yakima Regional Cancer Care
Yakima, Washington, United States, 98902
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792-5156
Sponsors and Collaborators
Gilead Sciences
Investigators
Study Director: Thomas Jahn, MD Gilead Sciences
  More Information

No publications provided by Gilead Sciences

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT01090414     History of Changes
Other Study ID Numbers: 101-99
Study First Received: March 17, 2010
Last Updated: October 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Gilead Sciences:
Idelalisib
Chronic lymphocytic leukemia (CLL)
Non-Hodgkin lymphoma (NHL)
Phosphatidylinositol 3-kinase (PI3K)

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma
Lymphoma, Non-Hodgkin
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on November 24, 2014